Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Rickenbach

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
AIDS (London, England)|December 4, 2004
Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre studyClaudine Zellweger, Milos Opravil, Enos Bernasconi, et al.
AIDS (London, England)|July 29, 2004
Is unsafe sexual behaviour increasing among HIV-infected individuals?Tracy R Glass, Jim Young, Pietro L Vernazza, et al.
Lancet (London, England)|August 2, 2005
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort studyJonathan A C Sterne, Miguel A Hernán, Bruno Ledergerber, et al.
Plos One|December 17, 2009
Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007Marie Ballif, Bruno Ledergerber, Manuel Battegay, et al.
AIDS (London, England)|July 20, 2002
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /lMilos Opravil, Bruno Ledergerber, Hansjakob Furrer, et al.
Antiviral Therapy|February 5, 2008
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modificationOlivia Keiser, Jacques Fellay, Milos Opravil, et al.
Antiviral Therapy|September 13, 2005
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort studyJim Young, Rainer Weber, Martin Rickenbach, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2007
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort StudyBruno Ledergerber, Hansjakob Furrer, Martin Rickenbach, et al.
Antiviral Therapy|March 9, 2005
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort studyJim Young, Martin Rickenbach, Rainer Weber, et al.
BMC Infectious Diseases|September 23, 2015
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort StudyJim Young, Martin Rickenbach, Alexandra Calmy, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
AIDS (London, England)|December 4, 2004
Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre studyClaudine Zellweger, Milos Opravil, Enos Bernasconi, et al.
AIDS (London, England)|July 29, 2004
Is unsafe sexual behaviour increasing among HIV-infected individuals?Tracy R Glass, Jim Young, Pietro L Vernazza, et al.
Lancet (London, England)|August 2, 2005
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort studyJonathan A C Sterne, Miguel A Hernán, Bruno Ledergerber, et al.
Plos One|December 17, 2009
Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007Marie Ballif, Bruno Ledergerber, Manuel Battegay, et al.
AIDS (London, England)|July 20, 2002
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /lMilos Opravil, Bruno Ledergerber, Hansjakob Furrer, et al.
Antiviral Therapy|February 5, 2008
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modificationOlivia Keiser, Jacques Fellay, Milos Opravil, et al.
Antiviral Therapy|September 13, 2005
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort studyJim Young, Rainer Weber, Martin Rickenbach, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2007
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort StudyBruno Ledergerber, Hansjakob Furrer, Martin Rickenbach, et al.
Antiviral Therapy|March 9, 2005
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort studyJim Young, Martin Rickenbach, Rainer Weber, et al.
BMC Infectious Diseases|September 23, 2015
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort StudyJim Young, Martin Rickenbach, Alexandra Calmy, et al.
Pageof 7